Metastasis
Metastasis | |
---|---|
Other names | Metastatic disease |
Illustration showing hematogenous metastasis | |
Pronunciation |
|
Specialty | Oncology |
Metastasis is a
Cancer occurs after cells are genetically altered to proliferate rapidly and indefinitely. This uncontrolled proliferation by
Some cancer cells known as
When tumor cells metastasize, the new tumor is called a secondary or metastatic tumor, and its cells are similar to those in the original or primary tumor.[8] This means that if breast cancer metastasizes to the lungs, the secondary tumor is made up of abnormal breast cells, not of abnormal lung cells. The tumor in the lung is then called metastatic breast cancer, not lung cancer. Metastasis is a key element in cancer staging systems such as the TNM staging system, where it represents the "M". In overall stage grouping, metastasis places a cancer in Stage IV. The possibilities of curative treatment are greatly reduced, or often entirely removed when a cancer has metastasized.
Signs and symptoms
Initially, nearby lymph nodes are struck early.
- In lymph node metastasis, a common symptom is lymphadenopathy
- dyspnea[9](shortness of breath)
- Liver metastasis: hepatomegaly (enlarged liver), nausea[9] and jaundice[9]
- Bone metastasis: bone pain,[9] fracture of affected bones[9]
- vertigo[9]
Although advanced cancer may cause pain, it is often not the first symptom.
Some patients, however, do not show any symptoms.[9] When the organ gets a metastatic disease it begins to shrink until its
Pathophysiology
Metastatic tumors are very common in the late stages of cancer. The spread of metastasis may occur via the blood or the lymphatics or through both routes. The most common sites of metastases are the lungs, liver, brain, and the bones.[10]
Currently, three main theories have been proposed to explain the metastatic pathway of cancer: the epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) hypothesis (1), the cancer stem cell hypothesis (2), and the macrophage–cancer cell fusion hybrid hypothesis (3). Some new hypotheses were suggested as well, i.e., under the effect of particular biochemical and/or physical stressors, cancer cells can undergo nuclear expulsion with subsequent macrophage engulfment and fusion, with the formation of cancer fusion cells (CFCs).[11] Understanding the enigma of cancer cell spread to distant sites, which accounts for over 90% of cancer-related deaths, necessitates comprehensive investigation. Key outstanding questions revolve around the survival and migration of cancer cells, such as the nucleus, as they face challenges in passage through capillary valves and hydrodynamic shear forces in the circulation system, making CTCs an unlikely source of metastasis. Moreover, understanding how cancer cells adapt to the metastatic niche and remain dormant (tumor dormancy) for extended periods presents difficult questions that require further investigation.[12]
Factors involved
Metastasis involves a complex series of steps in which cancer cells leave the original tumor site and migrate to other parts of the body via the bloodstream, via the lymphatic system, or by direct extension. To do so, malignant cells break away from the primary tumor and attach to and degrade
Human cells exhibit different kinds of motion: collective motility, mesenchymal-type movement, and amoeboid movement. Cancer cells often opportunistically switch between different kinds of motion. Some cancer researchers hope to find treatments that can stop or at least slow down the spread of cancer by somehow blocking some necessary step in one or more kinds of motion.[17][18]
All steps of the metastatic cascade involve a number of physical processes. Cell migration requires the generation of forces, and when cancer cells transmigrate through the vasculature, this requires physical gaps in the blood vessels to form.[19] Besides forces, the regulation of various types of cell-cell and cell-matrix adhesions is crucial during metastasis.
The metastatic steps are critically regulated by various cell types, including the blood vessel cells (endothelial cells), immune cells or stromal cells. The growth of a new network of blood vessels, called tumor angiogenesis,[20] is a crucial hallmark of cancer. It has therefore been suggested that angiogenesis inhibitors would prevent the growth of metastases.[7] Endothelial progenitor cells have been shown to have a strong influence on metastasis and angiogenesis.[21][22] Endothelial progenitor cells are important in tumor growth, angiogenesis and metastasis, and can be marked using the Inhibitor of DNA Binding 1 (ID1). This novel finding meant that investigators gained the ability to track endothelial progenitor cells from the bone marrow to the blood to the tumor-stroma and even incorporated in tumor vasculature. Endothelial progenitor cells incorporated in tumor vasculature suggests that this cell type in blood-vessel development is important in a tumor setting and metastasis. Furthermore, ablation of the endothelial progenitor cells in the bone marrow can lead to a significant decrease in tumor growth and vasculature development. Therefore, endothelial progenitor cells are important in tumor biology and present novel therapeutic targets.[23] The immune system is typically deregulated in cancer and affects many stages of tumor progression, including metastasis.
Epigenetic regulation also plays an important role in the metastatic outgrowth of disseminated tumor cells. Metastases display alterations in histone modifications, such as H3K4-methylation and H3K9-methylation, when compared to matching primary tumors.[24] These epigenetic modifications in metastases may allow the proliferation and survival of disseminated tumor cells in distant organs.[25]
A recent study shows that PKC-iota promotes melanoma cell invasion by activating Vimentin during EMT. PKC-iota inhibition or knockdown resulted in an increase in E-cadherin and RhoA levels while decreasing total Vimentin, phosphorylated Vimentin (S39) and Par6 in metastatic melanoma cells. These results suggested that PKC-ι is involved in signaling pathways which upregulate EMT in melanoma thereby directly stimulates metastasis.[26]
Recently, a series of high-profile experiments suggests that the co-option of intercellular cross-talk mediated by exosome vesicles is a critical factor involved in all steps of the invasion-metastasis cascade.[27]
Routes
Metastasis occurs by the following four routes:
Transcoelomic
The spread of a malignancy into body cavities can occur via penetrating the surface of the peritoneal, pleural, pericardial, or subarachnoid spaces. For example, ovarian tumors can spread transperitoneally to the surface of the liver.
Lymphatic spread
Lymphatic spread allows the transport of tumor cells to regional lymph nodes near the primary tumor and ultimately, to other parts of the body. This is called nodal involvement, positive nodes, or regional disease. "Positive nodes" is a term that would be used by medical specialists to describe regional lymph nodes that tested positive for malignancy. It is common medical practice to test by biopsy at least one lymph node near a tumor site when carrying out surgery to examine or remove a tumor. This lymph node is then called a sentinel lymph node. Lymphatic spread is the most common route of initial metastasis for carcinomas.[7] In contrast, it is uncommon for a sarcoma to metastasize via this route. Localized spread to regional lymph nodes near the primary tumor is not normally counted as a metastasis, although this is a sign of a worse outcome. The lymphatic system does eventually drain from the thoracic duct and right lymphatic duct into the systemic venous system at the venous angle and into the brachiocephalic veins, and therefore these metastatic cells can also eventually spread through the haematogenous route.
Hematogenous spread
This is typical route of metastasis for sarcomas, but it is also the favored route for certain types of carcinoma, such as renal cell carcinoma originating in the kidney and follicular carcinomas of the thyroid. Because of their thinner walls, veins are more frequently invaded than are arteries, and metastasis tends to follow the pattern of venous flow. That is, hematogenous spread often follows distinct patterns depending on the location of the primary tumor. For example, colorectal cancer spreads primarily through the portal vein to the liver.
Canalicular spread
Some tumors, especially
Organ-specific targets
There is a propensity for certain tumors to seed in particular organs. This was first discussed as the "seed and soil" theory by
According to the "seed and soil" theory, it is difficult for cancer cells to survive outside their region of origin, so in order to metastasize they must find a location with similar characteristics.
In 1928, James Ewing challenged the "seed and soil" theory and proposed that metastasis occurs purely by anatomic and mechanical routes. This hypothesis has been recently utilized to suggest several hypotheses about the life cycle of circulating tumor cells (CTCs) and to postulate that the patterns of spread could be better understood through a 'filter and flow' perspective.[32] However, contemporary evidences indicate that the primary tumour may dictate organotropic metastases by inducing the formation of pre-metastatic niches at distant sites, where incoming metastatic cells may engraft and colonise.[27] Specifically, exosome vesicles secreted by tumours have been shown to home to pre-metastatic sites, where they activate pro-metastatic processes such as angiogenesis and modify the immune contexture, so as to foster a favourable microenvironment for secondary tumour growth.[27]
Metastasis and primary cancer
It is theorized that metastasis always coincides with a primary cancer, and, as such, is a tumor that started from a cancer cell or cells in another part of the body. However, over 10% of patients presenting to
The use of immunohistochemistry has permitted pathologists to give an identity to many of these metastases. However, imaging of the indicated area only occasionally reveals a primary. In rare cases (e.g., of melanoma), no primary tumor is found, even on autopsy. It is therefore thought that some primary tumors can regress completely, but leave their metastases behind. In other cases, the tumor might just be too small and/or in an unusual location to be diagnosed.
Diagnosis
The cells in a metastatic tumor resemble those in the primary tumor. Once the cancerous tissue is examined under a microscope to determine the cell type, a doctor can usually tell whether that type of cell is normally found in the part of the body from which the tissue sample was taken.
For instance,
Metastatic cancers may be found at the same time as the primary tumor, or months or years later. When a second tumor is found in a patient that has been treated for cancer in the past, it is more often a metastasis than another primary tumor.
It was previously thought that most cancer cells have a low metastatic potential and that there are rare cells that develop the ability to metastasize through the development of somatic mutations.[35] According to this theory, diagnosis of metastatic cancers is only possible after the event of metastasis. Traditional means of diagnosing cancer (e.g. a biopsy) would only investigate a subpopulation of the cancer cells and would very likely not sample from the subpopulation with metastatic potential.[36]
The
Expression of this metastatic signature has been correlated with a poor prognosis and has been shown to be consistent in several types of cancer. Prognosis was shown to be worse for individuals whose primary tumors expressed the metastatic signature.[36] Additionally, the expression of these metastatic-associated genes was shown to apply to other cancer types in addition to adenocarcinoma. Metastases of breast cancer, medulloblastoma and prostate cancer all had similar expression patterns of these metastasis-associated genes.[36]
The identification of this metastasis-associated signature provides promise for identifying cells with metastatic potential within the primary tumor and hope for improving the prognosis of these metastatic-associated cancers. Additionally, identifying the genes whose expression is changed in metastasis offers potential targets to inhibit metastasis.[36]
-
papillary thyroid carcinoma) in a lymph node of the neck. H&E stain
-
CT imageof multiple liver metastases
-
CT imageof a lung metastasis
-
Metastatic cancer in the lungs
-
Metastases from the lungs to the brain
-
Metastases from the lungs to the pancreas
Management
Treatment and survival is determined, to a great extent, by whether or not a cancer remains localized or spreads to other locations in the body. If the cancer metastasizes to other tissues or organs it usually dramatically increases a patient's likelihood of death. Some cancers—such as some forms of leukemia, a cancer of the blood, or malignancies in the brain—can kill without spreading at all.
Once a cancer has metastasized it may still be treated with
Current treatments are rarely able to cure metastatic cancer though some tumors, such as testicular cancer and thyroid cancer, are usually curable.
Palliative care, care aimed at improving the quality of life of people with major illness, has been recommended as part of management programs for metastasis.[39] Results from a systematic review of the literature on radiation therapy for brain metastases found that there is little evidence to inform comparative effectiveness and patient-centered outcomes on quality of life, functional status, and cognitive effects.[40]
Research
Although metastasis is widely accepted to be the result of the tumor cells migration, there is a hypothesis saying that some metastases are the result of inflammatory processes by abnormal immune cells.[41] The existence of metastatic cancers in the absence of primary tumors also suggests that metastasis is not always caused by malignant cells that leave primary tumors.[42]
The research done by Sarna's team proved that heavily pigmented melanoma cells have Young's modulus about 4.93, when in non-pigmented ones it was only 0.98.[43] In another experiment they found that elasticity of melanoma cells is important for its metastasis and growth: non-pigmented tumors were bigger than pigmented and it was much easier for them to spread. They shown that there are both pigmented and non-pigmented cells in melanoma tumors, so that they can both be drug-resistant and metastatic.[43]
History
The first physician to report the possibility of local metastasis from a primary cancerous source to nearby tissues was Ibn Sina. He described a case of breast cancer and metastatic condition in The Canon of Medicine. His hypothesis was based on clinical course of the patient.[44][45]
In March 2014 researchers discovered the oldest complete example of a human with metastatic cancer. The tumors had developed in a 3,000-year-old skeleton found in 2013 in a tomb in
Etymology
Metastasis is a
See also
- Abscopal effect
- Brain metastasis
- Brown-Séquard syndrome (Sections on cavernous malformation, germinoma, renal cell carcinoma and lung cancer)
- Collective cell migration
- Contact normalization
- Disseminated disease
- Micrometastasis
- Mouse models of breast cancer metastasis
- Positron emission tomography (PET)
- Urogenital pelvic malignancy
References
- ^ "Metastasis", Merriam–Webster online, accessed 20 Aug 2017.
- ^ "What is Metastasis?". Cancer.Net. 2 February 2016.
- S2CID 206515808.
- PMID 19109576.
- ^ "Invasion and metastasis". Cancer Australia. 2014-12-16. Retrieved 2018-10-26.
- PMID 20071161.
- ^ ISBN 978-0-7216-0187-8.
- ^ "O que é a metástase?" (in Brazilian Portuguese). Dr. Felipe Ades MD PhD—Oncologista. 2018-07-24. Retrieved 2018-10-23.
- ^ a b c d e f g h i j k National Cancer Institute: Metastatic Cancer: Questions and Answers. Retrieved on<rc-c2d-number> 2008-11-01</rc-c2d-number>
- ^ "Metastatic Cancer: Questions and Answers". National Cancer Institute. Retrieved 2008-08-28.
- ^ Olteanu G-E, Mihai I-M, Bojin F, Gavriliuc O, Paunescu V. The natural adaptive evolution of cancer: The metastatic ability of cancer cells. Bosn J of Basic Med Sci [Internet]. 2020Feb.3;. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/4565
- PMID 32020846.
- S2CID 17745552.
- S2CID 34438005.
- PMID 21494783.
- PMID 11058615.
- ^ Matteo Parri, Paola Chiarugi. "Rac and Rho GTPases in cancer cell motility control" 2010
- S2CID 5547981.
- PMID 31048903.
- PMID 1701519.
- S2CID 12577022.
- PMID 17575055.
- PMID 20807818.
- PMID 23520493.
- PMID 19177007.
- PMID 29048609.
- ^ PMID 27157716.
- ^ List of included entries and references is found on main image page in Commons: Commons:File:Metastasis sites for common cancers.svg#Summary
- S2CID 26736196.
- S2CID 19573769.
- ISBN 978-0-8153-4076-8. quoted in Angier N (3 April 2007). "Basics: A mutinous group of cells on a greedy, destructive task". The New York Times.
- PMID 22912952.
- PMID 22157556.
- ^ PMID 10388044.
- S2CID 4302076.
- ^ S2CID 12059602.
- S2CID 4369266.
- PMID 29342134.
- S2CID 6743524.
- PMID 34119447.
- PMID 27158448.
- PMID 26097879.
- ^ PMID 31243305.
- PMID 27810694.
- PMID 34466487.
- ^ Kelland K (17 March 2014). "Archaeologists discover earliest example of human with cancer". Reuters. Retrieved 18 March 2014.
- ^ Ghosh P (18 March 2014). "Ancient skeleton is the earliest case of cancer yet detected". BBC. Retrieved 18 March 2014.
- ^ Ross P (17 March 2014). "Possible Oldest Cancer Found In 3,000-Year-Old Skeleton Could Reveal 'Evolution' Of Modern Disease". International Business Times. Retrieved 18 March 2014.